Dracen Pharmaceuticals Patents – Insights & Stats (Updated 2023)

Dracen Pharmaceuticals has a total of 41 patents globally, out of which no patents have been granted. Of these 41 patents, more than 85% patents are active. Europe is where Dracen Pharmaceuticals has filed the maximum number of patents, followed by Japan, United States of America and Israel. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Dracen Pharmaceuticals.

Dracen Pharmaceuticals was founded in 2016. The company creates innovative glutamine antagonists in order to enhance the results of cancer patients.

Do read about some of the most popular patents of Dracen Pharmaceuticals which have been covered by us in this article and also you can find Dracen Pharmaceuticals patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Dracen Pharmaceuticals patent portfolio.

How many patents does Dracen Pharmaceuticals have?

Dracen Pharmaceuticals has a total of 41 patents globally. These patents belong to 6 unique patent families. Out of 41 patents, 35 patents are active.

How Many Patents did Dracen Pharmaceuticals File Every Year?

Dracen Pharmaceuticals Patent Filing Trend

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or GrantDracen Pharmaceuticals Applications FiledDracen Pharmaceuticals Patents Granted
20231
20219
202026
20226

How many Dracen Pharmaceuticals patents are Alive/Dead?

Worldwide Patents

Dracen Pharmaceuticals Patent Portfolio

How Many Patents did Dracen Pharmaceuticals File in Different Countries?

Dracen Pharmaceuticals Worldwide Patent Filing

Countries in which Dracen Pharmaceuticals Filed Patents

CountryPatent
Europe5
Japan4
United States of America4
Israel4
Hong Kong (S.A.R.)3
Canada3
Singapore2
Australia2
Brazil2
South Africa2
Mexico2
India2
New Zealand1

Where are Research Centers of Dracen Pharmaceuticals Patents Located?

The Research Center for Dracen Pharmaceuticals is the United States of America.

What Percentage of Dracen Pharmaceuticals US Patent Applications Were Granted?

Dracen Pharmaceuticals (Excluding its subsidiaries) has filed 1 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 0 have been granted leading to a grant rate of 0%.

Below are the key stats of Dracen Pharmaceuticals patent prosecution at the USPTO.

Which Law Firms Filed Most US Patents for Dracen Pharmaceuticals?

Law FirmTotal ApplicationsSuccess Rate
Sterne Kessler Goldstein & Fox10%

List of Dracen Pharmaceuticals patents

Dracen Pharmaceuticals PatentsTitle
US11760723B2Method Of Preparing A Don Prodrug From L-Pyroglutamic Acid
US20220332676A1Lyophilized Composition Comprising (S)-Isopropyl 2-((S)-2-Acetamido-3-(1H-Indol-3-Yl)Propanamido)-6-Diazo-5-Oxohexanoate For Intravenous Administration And The Use Thereof
US20220117938A1Combinaton Therapy With A Don Prodrug And An Immune Checkpoint Inhibitor
US20220089522A1Method Of Preparing A Don Prodrug From L-Glutamic Acid
EP4037674A4Lyophilized Composition Comprising (S)-Isopropyl 2-((S)-2-Acetamido-3-(1H-Indol-3-Yl)Propanamido)-6-Diazo-5-Oxohexanoate For Intravenous Administration And The Use Thereof
EP4221842A1Lyophilized Composition Comprising (S)-Isopropyl 2-((S)-2- Acetamido-3-(1H-Indol-3-Yl)Propanamido)-6-Diazo-5- Oxohexanoate For Subcutaneous Administration And The Use Thereof
EP3923934A4Method Of Preparing A Don Prodrug From L-Pyroglutamic Acid
EP3911310A4Combinaton Therapy With A Don Prodrug And An Immune Checkpoint Inhibitor
WO2022261117A1Combination Therapy With A Don Prodrug And A Tigit Inhibitor
CA3153424A1Lyophilized Composition Comprising (S)-Isopropyl 2-((S)-2-Acetamido-3-(1H-Indol-3-Yl)Propanamido)-6-Diazo-5-Oxohexanoate For Intravenous Administration And The Use Thereof
CA3129136A1Method Of Preparing A Don Prodrug From L-Pyroglutamic Acid
CA3126822A1Combinaton Therapy With A Don Prodrug And An Immune Checkpoint Inhibitor
JP2022518232A5Combination Therapy With Don Prodrugs And Immune Checkpoint Inhibitors
JP2022552168AFrozen Containing (S)-Isopropyl 2-((S)-2-Acetamido-3-(1H-Indol-3-Yl)Propanamide)-6-Diazo-5-Oxohexanoate For Intravenous Administration Dry Composition And Its Use
JP2022519574AMethod For Preparing Don Prodrugs From L-Glutamic Acid
JP2022519530AMethod For Preparing Don Prodrugs From L-Pyroglutamic Acid
AU2020356925A1Lyophilized Composition Comprising (S)-Isopropyl 2-((S)-2-Acetamido-3-(1H-Indol-3-Yl)Propanamido)-6-Diazo-5-Oxohexanoate For Intravenous Administration And The Use Thereof
AU2020208637A1Combinaton Therapy With A Don Prodrug And An Immune Checkpoint Inhibitor
HK40066185AMethod Of Preparing A Don Prodrug From L-Glutamic Acid
HK40065802AMethod Of Preparing A Don Prodrug From L-Pyroglutamic Acid
HK40062578ACombinaton Therapy With A Don Prodrug And An Immune Checkpoint Inhibitor
MX2022004014ALyophilized Composition Comprising (S)-Isopropyl 2-((S)-2-Acetamido-3-(1H-Indol-3-Yl)Propanamido)-6-Diazo-5-Oxoh Exanoate For Intravenous Administration And The Use Thereof.
MX2021008546ACombinaton Therapy With A Don Prodrug And An Immune Checkpoint Inhibitor.
IL291850ALyophilized Composition Comprising (S)-Isopropyl 2-((S)-2-Acetamido-3-(1H-Indol-3-Yl)Propanamido)-6-Diazo-5-Oxohexanoate For Intravenous Administration And The Use Thereof
ZA202204864ALyophilized Composition Comprising (S)-Isopropyl 2-((S)-2-Acetamido-3-(1H-Indol-3-Yl)Propanamido)-6-Diazo-5-Oxohexanoate For Intravenous Administration And The Use Thereof
SG11202203349QALyophilized Composition Comprising (S)-Isopropyl 2-((S)-2-Acetamido-3-(1H-Indol-3-Yl)Propanamido)-6-Diazo-5-Oxohexanoate For Intravenous Administration And The Use Thereof
IN202117039458AMethod Of Preparing A Don Prodrug From L-Glutamic Acid
IN202117037862AMethod Of Preparing A Don Prodrug From L-Pyroglutamic Acid
BR112021014112A2Uses Of Don Pro-Drug Compound And Immune Control Point Inhibitor To Treat Cancer, As Well As Compound And Pharmaceutical Composition Comprising The Same
IL285470AMethod Of Preparing A Don Prodrug From L-Glutamic Acid
IL285459AMethod Of Preparing A Don Prodrug From L-Pyroglutamic Acid
IL284907ACombinaton Therapy With A Don Prodrug And An Immune Checkpoint Inhibitor
SG11202107317WACombinaton Therapy With A Don Prodrug And An Immune Checkpoint Inhibitor
ZA202105841ACombinaton Therapy With A Don Prodrug And An Immune Checkpoint Inhibitor
NZ787820ALyophilized Composition Comprising (S)-Isopropyl 2-((S)-2-Acetamido-3-(1H-Indol-3-Yl)Propanamido)-6-Diazo-5-Oxohexanoate For Intravenous Administration And The Use Thereof
EP3924330A4Method Of Preparing A Don Prodrug From L-Glutamic Acid
WO2022072820A1Lyophilized Composition Comprising (S)-Isopropyl 2-((S)-2- Acetamido-3-(1H-Indol-3-Yl)Propanamido)-6-Diazo-5- Oxohexanoate For Subcutaneous Administration And The Use Thereof
WO2020167829A1Method Of Preparing A Don Prodrug From L-Pyroglutamic Acid
WO2020167831A1Method Of Preparing A Don Prodrug From L-Glutamic Acid
WO2020150639A1Combinaton Therapy With A Don Prodrug And An Immune Checkpoint Inhibitor
BR112022006409A2Lyophylized Composition Comprising (S)-Isopropyl 2-((S)-2-Acetamido-3-(1H-Indol-3-Yl)Propanamido)-6-Diazo-5-Oxo-Hexanoate For Intravenous Administration And Use Of Same

What are Dracen Pharmaceuticals key innovation segments?

What Technologies are Covered by Dracen Pharmaceuticals?

The chart below distributes patents filed by Dracen Pharmaceuticals in different countries on the basis of the technology protected in patents. It also represents the markets where Dracen Pharmaceuticals thinks it’s important to protect particular technology inventions.

R&D Focus: How has Dracen Pharmaceuticals search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Dracen Pharmaceuticals?

Related Articles

MRM Patents – Insights & Stats (Updated 2024)

MRM has a total of 112 patents globally, out of which 64 have been granted. Of these 112 patents, more than 73% patents are active. United States of America is where MRM has filed the maximum number of patents, followed by China and Australia. Parallelly, Australia seems to be the

Read More »

I Peace Patents – Insights & Stats (Updated 2024)

I Peace has a total of 260 patents globally, out of which 53 have been granted. Of these 260 patents, more than 75% patents are active. Japan is where I Peace has filed the maximum number of patents, followed by The United States of America and Hong Kong (S.A.R.). Parallelly,

Read More »

Leave a Comment

Fill the form to get the details:

Our comprehensive report provides an in-depth look into the patent portfolio. The report includes a breakdown of the patent portfolio across various technologies, listing the patent along with brief summaries of each patent's technology.